Lexapro
- All
- News
-
New Drug May Treat Depression in 24 Hours
In a breakthrough, scientists have identified promising compounds that could successfully treat depression in less than 24 hours with minimal side effects.
-
Aurobindo Pharma gets US drug regulator's approval for anti-depressant
Aurobindo Pharma today said it has received final approval from the US health regulator to manufacture and market generic version of anti-depressant Lexapro in the American market. The approval by the US Food & Drug Administration (USFDA) is for multiple strengths of escitalopram oxalate tablets in 5mg, 10mg and 20mg, the company said in a statemen...
-
Cipla shares jump 6% on robust Q1, positive commentary
The domestic formulation business grew 30%, which was way above the Street estimates of 17% growth.
-
Cipla gains; CLSA says stock will 'outperform'
Shares in Cipla gain 3.1 per cent to Rs 327.35 after CLSA upgrades the stock to "outperform" from "underperform".
-
New Drug May Treat Depression in 24 Hours
In a breakthrough, scientists have identified promising compounds that could successfully treat depression in less than 24 hours with minimal side effects.
-
Aurobindo Pharma gets US drug regulator's approval for anti-depressant
Aurobindo Pharma today said it has received final approval from the US health regulator to manufacture and market generic version of anti-depressant Lexapro in the American market. The approval by the US Food & Drug Administration (USFDA) is for multiple strengths of escitalopram oxalate tablets in 5mg, 10mg and 20mg, the company said in a statemen...
-
Cipla shares jump 6% on robust Q1, positive commentary
The domestic formulation business grew 30%, which was way above the Street estimates of 17% growth.
-
Cipla gains; CLSA says stock will 'outperform'
Shares in Cipla gain 3.1 per cent to Rs 327.35 after CLSA upgrades the stock to "outperform" from "underperform".
